Propanc Biopharma Advances Recombinant Cancer Therapy with Peer-Reviewed Findings
Event summary
- Propanc Biopharma published research in Microbial Cell Factories on recombinant trypsinogen and chymotrypsinogen production for chronic disease treatment.
- The study, conducted with Universities of Jaén and Granada, demonstrated scalable production of proenzymes using recombinant technology.
- Rec-PRP, the recombinant version of PRP, is being developed as a backup to Propanc’s lead asset targeting metastatic cancer.
- PRP is scheduled for Phase 1b clinical trials in early 2027, with rec-PRP potentially offering longer shelf life and global distribution advantages.
The big picture
Propanc’s recombinant approach aligns with broader biotech trends toward synthetic production of therapeutic proteins, reducing reliance on animal-derived sources. The $111 billion metastatic cancer market presents significant growth potential, but success hinges on demonstrating clinical efficacy and regulatory compliance for rec-PRP.
What we're watching
- Regulatory Pathway
- How Propanc will navigate regulatory approval for rec-PRP, given its non-GMP production phase.
- Market Expansion
- Whether the recombinant technology can extend PRP’s reach into developing regions with limited refrigeration.
- Clinical Success
- The pace at which rec-PRP could become a viable alternative to bovine-sourced PRP in treating metastatic cancer.
Related topics